Cardiovascular risk reduction more prominent with EPA monotherapy versus EPA + DHA therapy
MONDAY, July 12, 2021 (HealthDay News) — Omega-3 fatty acids (FAs) are associated with lower cardiovascular mortality and improved cardiovascular outcomes, according to a review published online July 8 in eClinicalMedicine.
Safi U. Khan, M.B.B.S., from West Virginia University in Morgantown, and colleagues conducted a systematic literature review to determine the effectiveness of omega-3 FAs on fatal and nonfatal cardiovascular outcomes. The meta-analysis included 38 randomized controlled trials (149,051 participants) of omega-3 FAs, stratified by eicosapentaenoic acid (EPA) monotherapy and EPA + docosahexaenoic acid (DHA) therapy.
The researchers found that omega-3 FA intake was associated with reductions in cardiovascular mortality (rate ratio [RR], 0.93), nonfatal myocardial infarction (MI; RR, 0.87), coronary heart disease (CHD) events (RR, 0.91), major adverse cardiovascular events (MACE; RR, 0.95), and revascularization (RR, 0.91). EPA monotherapy was associated with higher risk reductions than EPA + DHA for cardiovascular mortality, nonfatal MI, CHD events, MACE, and revascularization. However, omega-3 FA increased incident atrial fibrillation (RR, 1.26), while EPA monotherapy was associated with a higher risk for total bleeding (RR, 1.49) and atrial fibrillation (RR, 1.35) compared with control.
“This study provides evidence regarding the therapeutic efficacy of omega-3 FAs and may explain the conflicting results between EPA monotherapy trials and those with EPA + DHA,” the authors write.
Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.
Iron Supplementation Likely to Reduce Iron-Deficiency Anemia in Children
Vitamin C Supplements in Pregnancy May Boost Infant Emotional Well-Being
Recommendations Issued for Use of Incretin-Based Meds in Pregnancy
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
CDC: 1 in 10 U.S. Adults Reported GLP-1 Medication Use July to August 2025
β3 Agonists Do Not Cut Dementia Risk Versus Anticholinergics in OAB
Few Meet Major Clinical Response Criteria After Treatment Escalation for Lupus
Postoperative Complications Elevated for Patients With Systemic Lupus Erythematosus